Johnson & Johnson Announces U.S. FDA Approval of Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as First and Only Dual-Targeted Therapy for Advanced Head and Neck Cancer

Nov 10, 2026 - 20:00
 0  0
New Brunswick, N.J. (November 5, 2026) – Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval for Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) (subcutaneous...

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0